Local Prescribing Information:

US-FDA Approved Foundation Medicine's FoundationOne®Liquid CDx, a Pan-Tumor Liquid Biopsy Genomic Test for Late Stage Cancer Patients now Available in India

Roche Pharma India expands partnership with Cipla to further improve access to key oncology medicine

Roche’s Atezolizumab receives DCGI approval for treatment of metastatic triple-negative breast cancer in India 

V. Simpson Emmanuel appointed as General Manager, Roche Products (India) Pvt. Ltd. 

Safety Update Information for Healthcare Professionals (Oncology):

DIL and DHPC package issued for Tecentriq regarding SCARs (Severe Cutaneous Adverse Reactions) s an Identified Risk dated 6th Nov 2020

5-Fluorouracil (i.v.), Capecitabine and Tegafur containing products Pre-treatment testing to identify DPDdeficient patients at increased risk of severe toxicity dated 19th May 2020

DHPC Tecetriq Atezolizumab Injection 1200mg20ml Safety Update Identified risk -Immune-related myositis dated 31st January 2019

DHCP Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated 3rd October 2018

DHPC Tecentriq Atezolizumab Injection 1200mg20ml Important Identified risk immune related nephritis dated 30th July, 2018

DHCP Tecentriq Atezolizumab Injection 1200MG..20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated July 23, 2018